| (Values in U.S. Thousands) | Aug, 2025 | May, 2025 | Nov, 2024 | Aug, 2024 | May, 2024 |
| Sales | 27 | 36 | 35 | 27 | 41 |
| Sales Growth | -24.24% | +2.90% | +30.66% | -35.32% | +155.85% |
| Net Income | -11 | 0 | -27 | -9 | -83 |
| Net Income Growth | -3,585.71% | +98.90% | -195.30% | +89.05% | +15.32% |
Optimind Pharma Corp. (OMND.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Optimind Pharma Corp, through its clinic, specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. It offers psychedelic-like therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted treatment and other psychedelic-enhanced psychotherapy modalities. The company is also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings.
Fiscal Year End Date: 02/28